Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t
Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the…
Johns Lyng Group (ASX:JLG): Taking the easy way out with a $1.1bn buyout
The tenure of Johns Lyng Group (ASX:JLG) is ending with Pacific Equity Partners buying it out for $1.1bn after several…
Here are 9 of the most successful hedge fund managers of all time
To say the most successful hedge fund managers have made a lot of money from the stock market is an…
SDI (ASX:SDI): Will slow and steady win the race?
If you’re looking for a stock that’ll make you a fortune, SDI (ASX:SDI) might not be the best one for…
Lifestyle Communities (ASX: LIC) Shares Plunged 38%: What the Exit Fees Tribunal Ruling Means for Investors
Lifestyle Communities (ASX: LIC) shares experienced a dramatic drop of around 38% after a Victorian Civil and Administrative Tribunal (VCAT)…
Orphan Drug Designation: What is it and why is it a big deal for biotech stocks?
While most small cap health stocks dream of commercialisation, healthcare companies at an early stage get excited about achieving Orphan…
ASX Real Estate Stocks Are Finally Out of the Doldrums: But These 6 Are Standing Above The Rest
FY25 was finally the year ASX Real Estate Stocks broke out of their post-COVID slump, netting an average return of…
Meta Platforms (NDQ:META): With 3bn+ users, is it the dark horse in the rapid AI race? And can we trust it after the VR and metaverse flops?
Let’s look at Meta Platforms (NDQ:META), a company that changed its name in 2021 thinking that the metaverse would be…
Top 5 ASX Penny Stocks That Outperformed the Market in 2025
Penny stocks have long been associated with high-risk, high-reward investing. For investors with a high tolerance for risk, these stocks…
Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?
Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this…
How can an investor beat the market? Here’s how to go about it
You may’ve heard the expression to ‘beat the market’. What does this mean? Well, it depends on the context in…
How to create a passive income from stocks in FY26? Here are 5 strategies
Most people invest in stocks for capital gains (in other words for selling the stock for more than they bought…
Percheron Therapeutics (ASX:PER) picks itself up in 2025
Percheron Therapeutics (ASX:PER) It’s a fact of life in the biotech game: drugs often fail in clinical development. Percheron Therapeutics…
Here’s why Kogan (ASX:KGN) should be on your watchlist for FY26
Kogan shares (ASX:KGN) have been volatile in the past couple of years, but is a better future ahead of it? At…